Thermo Fisher to Buy Coronavirus Tester Qiagen for $10 Billion

The video discusses the acquisition deal between Thermo Fisher and Kigen, highlighting how the coronavirus pandemic influenced the negotiations. Initially, talks broke down, but Thermo Fisher re-engaged with Kigen, leading to a deal at a price of $43 per share, which is a 30% premium. The acquisition, valued at $10 billion, is the largest healthcare acquisition of 2020. Despite potential interest from other companies, a bidding war is unlikely due to the structured breakup fee.

What event caused the initial deal talks between Kigen and Thermo Fisher to break down?

• A disagreement over the price

• A legal issue with the merger

• A competing offer from another company

• The impact of the coronavirus pandemic

How did the coronavirus pandemic influence the deal between Kigen and Thermo Fisher?

• It resulted in a competing bid from another company

• It led to a decrease in share prices

• It helped the companies reach a price agreement

• It caused the deal to be postponed indefinitely

What was the approximate share price agreed upon in the deal between Kigen and Thermo Fisher?

• $50 per share

• $60 per share

• $43 per share

• $30 per share

What was the total value of the acquisition deal between Kigen and Thermo Fisher?

• $10 billion

• $5 billion

• $15 billion

• $20 billion

Which companies were mentioned as potential competitors in the acquisition of Kigen?

• Roche and Novartis

• Danaher and Illumina

• Pfizer and Moderna

• Johnson & Johnson and Merck